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Clinical risk prediction models (CRPMs) are 
statistical models that aim to improve medical 
decision making by providing an objective 
measure of potential health outcomes based 
on data.1 In recent years, there has been 
an explosion in the development of such 
models across all areas of medical care. Addi-
tionally, the adjunct of artificial intelligence 
(AI), which builds on traditional statistical 
prediction methods using machine learning, 
models are increasing in complexity and 
potential accuracy.2 However, the adoption 
pathway of CRPMs and AI models is similar, 
with both requiring access to data for model 
development, regulatory approval and effec-
tive implementation into the workflow of 
clinicians.
Despite significant potential, only few 
CRPMs have been implemented into practice 
and achieved patient benefit.3 In this editorial 
we explore the incentives of producers, inter-
mediaries and users of CRPMs and discuss 
how a lack of alignment has failed to realise 
their potential to achieve intended benefits. 
AI in healthcare faces a similar threat and we 
propose a novel solution to mitigate this for 
the future.
Currently, models are mainly produced 
in the academic context, where there is 
access to data and methodological exper-
tise. Researchers are incentivised by tradi-
tional academic objectives, such as published 
papers, conference presentations or other 
scientific accolades. This results in a failure to 
pursue a successfully validated model beyond 
these goals. If further motivation (and often 
funding) allows, efforts are focused on 
improving the statistical accuracy or under-
taking external validation studies, rather 
than exploring implementation or clinical 
usability.
Furthermore, any software, such as a 
CRPM or a clinical AI model, is by definition 
a medical device.4 This means that they are 
subject to conformity assessments and regu-
latory approval prior to being placed on the 
market.5 Most researchers will not have the 
expertise to undertake this, or have access to 
the relevant support to navigate this process. 
Additionally, software requires regular 
updates and maintenance, which may come 
with considerable running costs. Currently, 
there is no clear understanding of whom to 
attribute these to, yet they are critical to the 
longer- term safety, efficacy and viability of a 
CRPM.
Clinically validated and approved models 
are typically implemented as stand- alone 
web or mobile applications. This creates 
usability barriers, as users access an external 
interface and manually transcribe data to 
receive results.6 In reality, electronic health 
record (EHR) vendors could act as interme-
diaries and integrate models directly into 
their systems, complementing the clinical 
workflow. However, the vendors would have 
to take responsibility for the medical device 
regulation, maintenance and associated costs. 
The value proposition for vendors to foot 
these costs and risks is currently not there, 
especially as clinical stakeholders do not yet 
expect such functionalities in EHRs. An alter-
native could be for vendors to provide third 
party companies an application program-
ming interface (API) to their EHR. However, 
as there is no single API standard, third party 
model suppliers would have to integrate 
with each EHR individually. This would be 
compounded with ongoing licensing fees, 
making for a precarious business model for 
what are usually small enterprises.
ALIGNING INCENTIVES WITH BLOCKCHAIN 
TECHNOLOGY
The individual incentives of the producers 
(researchers), intermediaries (EHR vendors) 
and users (healthcare providers) are 
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currently unaligned. The academic environment or EHR 
market has not incentivised the conversion of technical 
discovery to integrated product development, limiting 
the ‘bench- to- bedside’ pathway of CRPMs. To prevent a 
similar experience for AI models, we must develop strat-
egies that align incentives and create a value proposition 
for all involved parties.
A potential solution could be a national infrastructure; 
a marketplace for models, all clinically validated and 
compliant with medical device regulations. Blockchain, 
a form of distributed ledger technology (DLT), may 
facilitate such an infrastructure by securely hosting the 
marketplace and allowing the producers to be remuner-
ated when their model is used through smart contracts.
Blockchain is an open network of distributed data 
stored in secure blocks, which are available to all partici-
pants (known as ‘nodes’) on a network.7 By distributing 
blocks across all nodes, the data in the network is diffi-
cult to hack, change or corrupt, creating a traceable, 
immutable and secure record of transactions between 
nodes.8 Blockchain has therefore been widely discussed 
in the context of sharing electronic patient records.9 
Smart contracts are a digital technology that execute an 
financial transaction recorded in a blockchain when a 
predefined condition is met.10
Blockchain and DLT could support the implementation 
and financial reward for CRPMS: models could be published 
to the national marketplace, hosted on the blockchain and 
clinical data could be entered securely to receive results with 
a micro- payment triggered at every use, via smart contracts. 
Defining a national vendor- neutral API standard for models 
would make the marketplace accessible from all EHRs that 
implement it. A recognised body could regulate this process 
alongside an established framework, such as the UK govern-
ment’s guide to good practice for digital and data- driven 
health technologies.11 The traceability provided through a 
DLT- based solution would build trust among all stakeholders 
and allow a shared interest to develop.
An example of a CRPM that this could apply to is the 
CHA(2)DV(2)- VASc score, which is used to predict the risk 
of stroke in patients with atrial fibrillation, and thus guide 
the need for blood- thinning medication.12 The producers 
would publish their model to the marketplace, who would 
take the responsibility of assessment conformity and regu-
latory approval. Once the model is live, EHR vendors could 
integrate it into their interface using the standardised API.
This would increase the use of CRPMs by clinicians as they 
are incorporated into their workflow, provide a monetary 
incentive for researchers to pursue models to implementa-
tion and integration and finally, make EHRs that integrate 
CRPMs more attractive for healthcare providers to procure. 
Figure 1 illustrates this concept, highlighting how blockchain 
technology can align incentives and operationalise current 
and future CRPMs and AI models.
The traditional medical research path is linear with 
rigid objectives and little concern for commercialisa-
tion. However, it is evidence- focused and rightly, prior-
itises safety and regulation. In contrast, technology 
development is agile, iterative and focused on real- 
world application.13 There remains a need to create a 
joint culture across academic and industry stakeholders 
to harmonise expertise and develop meaningful digital 
health solutions. Recent efforts, such as the proposed 
Decision- support systems driven by artificial intelligence 
guidelines, support this by calling for early clinical evalu-
ation with a view to bridging the current implementation 
gap of AI models.14
The introduction of Chief Clinical Informatics Officers 
and digital strategies by healthcare providers will help 
regulate and adopt these technologies going forward,15 
however, a collaboration across the vendor industry 
remains essential. A drive towards business success may 
incentivise researchers, vendors and healthcare providers 
appropriately to pursue solutions and achieve intended 
benefits. Interdisciplinary and cross- industry health 
research, with a long- term focus on clinical impact can 
thus unlock the potential of CRPMs and AI, leading to 
radical change in patient care and outcomes.
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Figure 1 Conceptual representation of a vendor- neutral 
distributed ledger- based CRPM marketplace to maintain data 
security with the use of smart contracts to facilitate micro- 
payments. API, application programming interface; CRPMs, 
clinical risk prediction models; EHR, electronic health record.
3Sharma V, et al. BMJ Health Care Inform 2021;28:e100421. doi:10.1136/bmjhci-2021-100421
Open access
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Videha Sharma http:// orcid. org/ 0000- 0001- 7640- 1239
Angela Davies http:// orcid. org/ 0000- 0002- 3365- 7231
REFERENCES
 1 Steyerberg EW. Clinical prediction models. Springer, 2019.
 2 Bzdok D, Altman N, Krzywinski M. Statistics versus machine 
learning. Nat Methods 2018;15:233–4.
 3 Kwan JL, Lo L, Ferguson J, et al. Computerised clinical decision 
support systems and absolute improvements in care: meta- analysis 
of controlled clinical trials. BMJ 2020;370:m3216.
 4 Spanou D. Software as a medical device (SaMD): key definitions. 
IMDRF SaMD Working Group, 2013.
 5 MHRA G. Medical device stand- alone software including apps 
(including IVDMDs). UK Goverment Policy, 2019.
 6 Sharma V, Ali I, van der Veer S, et al. Adoption of clinical risk 
prediction tools is limited by a lack of integration with electronic 
health records. BMJ Health Care Inform 2021;28:e100253.
 7 Leeming G, Ainsworth J, Clifton DA. Blockchain in health care: hype, 
trust, and digital health. The Lancet 2019;393:2476–7.
 8 Cunningham J, Ainsworth J. Enabling patient control of personal 
electronic health records through distributed ledger technology. Stud 
Health Technol Inform 2018;245:45–8.
 9 Mayer AH, da Costa CA, Righi RdaR. Electronic health records 
in a blockchain: a systematic review. Health Informatics J 
2020;26:1273–88.
 10 Cannarsa M. Interpretation of contracts and smart contracts: smart 
interpretation or interpretation of smart contracts? In: European 
review of private law. 26, 2018.
 11 Public Health England Guidance. Guidance on social distancing for 
everyone in the UK, 2020.
 12 Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk 
stratification for predicting stroke and thromboembolism in atrial 
fibrillation using a novel risk factor- based approach: the euro heart 
survey on atrial fibrillation. Chest 2010;137:263–72.
 13 Steinberg D, Horwitz G, Zohar D. Building a business model in digital 
medicine. Nat Biotechnol 2015;33:910–20.
 14 WatkinsonP, CliftonD, CollinsG, et al. DECIDE- AI: new reporting 
guidelines to bridge the development- to- implementation gap in 
clinical artificial intelligence. Nat Med 2021;27:186–7.
 15 Wachter R. Making it work: harnessing the power of health 
information technology to improve care in England. London, UK: 
Department of Health, 2016.
